advertisement

Topcon

Top-Eight of the Royal Australian and New Zealand College of Ophthalmologists Annual Conference

November 14-18, 2004, Melbourne, Victoria, Australia

Anne Brooks

At the conference of the Royal Australian and New Zealand College of Ophthalmologists, Jack Cioffi spoke on structure-function in glaucoma and the progression from structural change to functional change, and the differing methods of measurement from macro to subcellular imaging. Stuart Graham gave the Ida Mann lecture: Glaucoma diagnosis - Man versus Machine.

  •  Use of intraoperative transconjunctival mitomycin-C in needling revisions of failing filtered blebs enhances the outcome.
  • Adjunctive anti-TGF b2 human monoclonal antibody as an anti-scarring agent for phacotrabeculectomy: 3-year results showed it was safe, but its effect was marginal on intraocular pressure, and disappointing.
  • Trabeculectomy with 90-second exposure to 5-FU was as effective as 5 minutes with fewer side effects.
  • The comparison of intraocular pressure by Pascal Dynamic Contour Tonometry (PDCT) and Goldmann's applanation tonometry. PDCT is independent of central corneal thickness.
  • Optic disc analysis: comparison between a 60D-lens graticule, computer measurement from fundus slides and a Z-screen stereoscopic assessment. Computer analysis and measurements of optic disc landmarks was a reliable research.
  • IOP and cerebrospinal fluid pressure effects upon retinal arteriolar blood flow. Peak retinal blood flow occurred at equivalent IOP of 10 mmHg, with relative preservation of flow at higher IOP until greater than 25 mmHg. A surprising fall in flow to IOP less than 12 mmHg may be due to lamina cribrosa movement and venous compression, raising implications regarding the aetiology of central retinal vein occlusion.
  • It was suggested that a protocol to facilitate interpretation of frequency doubling perimetry visual fields, that considers only nasal step field loss as significant, may have an acceptable degree of accuracy.
  • Neuroprotective a2 agonists have their target on the retinal ganglion cell in human and rat eyes. However in discussion a question was raised by the audience as to the role of amacrine cells.

Issue 6-3

Change Issue


advertisement

Oculus